17.50
0.29 (1.69%)
| 前收盘价格 | 17.21 |
| 收盘价格 | 17.16 |
| 成交量 | 425,628 |
| 平均成交量 (3个月) | 420,391 |
| 市值 | 6,198,321,152 |
| 预期市盈率 (P/E Forward) | 17.15 |
| 价格/销量 (P/S) | 1.21 |
| 股市价格/股市净资产 (P/B) | 0.940 |
| 52周波幅 | |
| 利润日期 | 29 Oct 2025 |
| 营业毛利率 | -7.50% |
| 营业利益率 (TTM) | -5.36% |
| 稀释每股收益 (EPS TTM) | -1.02 |
| 季度收入增长率 (YOY) | 3.50% |
| 总债务/股东权益 (D/E MRQ) | 75.07% |
| 流动比率 (MRQ) | 1.56 |
| 营业现金流 (OCF TTM) | 166.00 M |
| 杠杆自由现金流 (LFCF TTM) | 69.00 M |
| 资产报酬率 (ROA TTM) | 0.61% |
| 股东权益报酬率 (ROE TTM) | -5.36% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 看涨 | 混合的 |
| Medical Instruments & Supplies (全球的) | 看涨 | 混合的 | |
| 股票 | Bausch + Lomb Corporation | 看涨 | 混合的 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.38 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Mid Core |
| 内部持股比例 | 88.13% |
| 机构持股比例 | 10.97% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Icahn Carl C | 30 Sep 2025 | 3,500,000 |
| Goldentree Asset Management Lp | 30 Sep 2025 | 2,660,508 |
| Silver Point Capital L.P. | 30 Sep 2025 | 2,565,000 |
| Diameter Capital Partners Lp | 30 Sep 2025 | 1,215,893 |
| Compass Rose Asset Management, Lp | 30 Sep 2025 | 1,000,000 |
| Davidson Kempner Capital Management Lp | 30 Sep 2025 | 980,474 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 21.00 (Morgan Stanley, 20.00%) | 购买 |
| 中 | 17.50 (0.00%) | |
| 低 | 16.00 (JP Morgan, -8.57%) | 保留 |
| 平均值 | 18.00 (2.86%) | |
| 总计 | 4 购买, 4 保留 | |
| 平均价格@调整类型 | 15.65 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Evercore ISI Group | 05 Jan 2026 | 18.00 (2.86%) | 保留 | 16.80 |
| 30 Oct 2025 | 18.00 (2.86%) | 购买 | 15.14 | |
| Morgan Stanley | 02 Dec 2025 | 21.00 (20.00%) | 购买 | 17.05 |
| RBC Capital | 14 Nov 2025 | 19.00 (8.57%) | 购买 | 15.60 |
| Wells Fargo | 14 Nov 2025 | 17.00 (-2.86%) | 保留 | 15.60 |
| 30 Oct 2025 | 16.00 (-8.57%) | 保留 | 15.14 | |
| Barclays | 31 Oct 2025 | 17.00 (-2.86%) | 保留 | 14.94 |
| HC Wainwright & Co. | 31 Oct 2025 | 17.00 (-2.86%) | 购买 | 14.94 |
| JP Morgan | 30 Oct 2025 | 16.00 (-8.57%) | 保留 | 15.14 |
| Raymond James | 30 Oct 2025 | 19.00 (8.57%) | 购买 | 15.14 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合